Karyopharm Therapeutics | KPTI - Trade Creditors


Karyopharm Therapeutics reported $4M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Abbott USD 4.24B 117M Dec/2025
Amgen USD 19.52B 1.37B Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
BioCryst Pharmaceuticals USD 15.83M 10.26M Dec/2025
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Incyte USD 228.62M 1.41B Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
MacroGenics USD 4.79M 1.15M Dec/2025
Merck USD 3.86B 541M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Novartis USD 4.32B 134M Mar/2026
Novartis USD 4.46B 99M Dec/2025
Pfizer USD 4.51B 734M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Takeda JPY 467.59B 28.61B Dec/2025
Tectonic Therapeutic USD 1.09M 392K Dec/2025
TG Therapeutics USD 61.64M 72.38M Sep/2025
Ultragenyx Pharmaceutical USD 31M 9.57M Dec/2025
Xencor USD 10.83M 1.75M Dec/2025